Read more
This multi-volume, state-of-the-art encyclopedia discusses all preclinical, clinical, toxicological, regulatory and marketing perspectives of drug metabolism and interactions. Methods and detailed protocols describing how to perform studies of metabolism and drug interactions are presented in one of the volumes. All aspects of drug metabolism and interactions in silico, in laboratory animals and in humans, are backed with a range of examples. This reference is essential for researchers interested in all aspects of drug development, and chemists, pharmacologists, pharmaceutical specialists, toxicologists, molecular toxicologists, and clinicians including practitioners and physicians.
List of contents
Contributors ix
Preface to the Encyclopedia xxiii
Preface--Volume 6 xxvii
PART X Clinical Aspects of Drug Metabolism and Interactions 1
1 Clinical Aspects of Drug Biotransformation: An Overview 3
Michael D. Coleman and Louis L. Radulovic
2 CYP450 Enzymes in Drug Discovery and Development: An Overview 53
Lin Xu, Biplab Das, and Chandra Prakash
3 DDI Risk Assessment and Evaluation in Pharmaceutical Development: Interfacing Drug Metabolism and Clinical Pharmacology 89
Karthik Venkatakrishnan
4 Current and Future Tools for Predicting Clinical Drug-Drug Interactions 151
Peter L. Bullock and Olga V. Trubetskoy
5 Predicting Human Biotransformation Pathways 177
Shelby Anderson, Debra Luffer-Atlas, and Mary Pat Knadler
6 Conjugation, Transport, and Elimination of Drugs in Humans 205
Ronald E. Savage
7 Role and Clinical Consequences of Human UDP-Glucuronosyltransferases 243
Deepak K. Dalvie and Cho-Ming Loi
8 Herb-Drug and Food-Drug Interactions 279
Martin S. Lennard
9 Effects of Liver Disease on Drug Metabolism in Humans 307
Hui-Hui Tan and Thomas D. Schiano
10 Role of Phase I Metabolism in Drug Activation and Clinical Treatment Outcomes 353
Bernard Testa and André Pannatier
11 Role of Metabolism in Toxicity of Drugs in Humans 377
Amit S. Kalgutkar and Jonathan N. Bauman
12 Idiosyncratic Drug Reactions and the Potential Role of Metabolism 403
Jack P. Uetrecht
PART XI Metabolism of Specific Drug Groups and Patient Populations 455
13 Metabolism of Psychotropic Drugs 457
Julia Stingl, Jessica Oesterheld, and Miia Turpeinen
14 Metabolism-Based Consequences of Polytherapy with Antiepileptic Drugs 473
Philip N. Patsalos
15 Oral Chemotherapeutic Agents 499
Shin Ogita, Patricia LoRusso, and Jing Li
16 Drug Metabolism and Interactions in Pediatric Patients 537
Souzan Yanni and Karel Allegaert
17 Population-Based Pharmacokinetic Modeling and Simulation 581
Frédéric Y. Bois and Masoud Jamei
18 Clinical Pharmacology in Drug Labeling. The Impact of Drug Metabolism and Clinical Pharmacology on Recommended Dose of Drugs 609
Stuart Dombey
Index 621
About the author
ALEXANDER V. LYUBIMOV, MD, PhD, DABT, is Director of the Toxicology Research Laboratory and Associate Professor of Pharmacology at the University of Illinois at Chicago. He has more than thirty years of experience in the fields of toxicology, bioanalytical chemistry, and drug efficacy. He has presented his research results at more than fifty national and international scientific conferences. In addition, he has published more than 140 scientific publications in peer-reviewed journals, books, and conference proceedings. Dr. Lyubimov has served as chair or president of several international conferences, including "Frontiers of Pharmacology and Toxicology," which he also organized.
Summary
This multi-volume, state-of-the-art encyclopedia discusses all preclinical, clinical, toxicological, regulatory and marketing perspectives of drug metabolism and interactions. Methods and detailed protocols describing how to perform studies of metabolism and drug interactions are presented in one of the volumes. All aspects of drug metabolism and interactions in silico, in laboratory animals and in humans, are backed with a range of examples. This reference is essential for researchers interested in all aspects of drug development, and chemists, pharmacologists, pharmaceutical specialists, toxicologists, molecular toxicologists, and clinicians including practitioners and physicians.
